Version 1
: Received: 8 April 2020 / Approved: 9 April 2020 / Online: 9 April 2020 (12:34:46 CEST)
Version 2
: Received: 21 April 2020 / Approved: 22 April 2020 / Online: 22 April 2020 (09:46:54 CEST)
How to cite:
Focosi, D.; Tuccori, M.; Maggi, F. ACE Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?. Preprints2020, 2020040151 (doi: 10.20944/preprints202004.0151.v2).
Focosi, D.; Tuccori, M.; Maggi, F. ACE Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?. Preprints 2020, 2020040151 (doi: 10.20944/preprints202004.0151.v2).
Cite as:
Focosi, D.; Tuccori, M.; Maggi, F. ACE Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?. Preprints2020, 2020040151 (doi: 10.20944/preprints202004.0151.v2).
Focosi, D.; Tuccori, M.; Maggi, F. ACE Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?. Preprints 2020, 2020040151 (doi: 10.20944/preprints202004.0151.v2).
Abstract
Human respiratory beta coronavirus are emerging causes for Public Health Emergencies of International Concern (PHEIC). SARS-CoV2 is circulating worldwide since November 2019. We review here the cardiovascular morbidity and mortality in COVID-19, and data supporting the role for dysregulation of the RAS counterregulatory axis due to binding of SARS-CoV2 S protein to ACE2 receptor. Since this counterregulatory axis provides benefits not only on the cardiovascular front but also in acute lung injury, we speculate on potential use of ACE inhibitors and AT1R blockers in critically ill COVID-19 patients, and report current evidences.
Keywords
COVID-19; ACEI; ARB; SARS; ALI; ARDS
Subject
LIFE SCIENCES, Virology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Commenter: Daniele Focosi
Commenter's Conflict of Interests: Author